← Leaderboards
Terry Burns
Mayo Clinic Rochester
$3,646,405
Attributed
$3,824,229
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,824,229 · 5
By mechanism
R37$1,580,138 · 1
R61$1,180,574 · 1
R21$438,774 · 1
R33$358,007 · 1
UH2$266,736 · 1
Top collaborators
- George Vasmatzis1 shared
- Gang Zheng1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Gang Zheng$88,912
- Jolene Summer Bolster$190,160
Others in their field
Other Emerging Leaders on “Recurrence”
- Manish Ishwar Shah · Baylor College Of Medicine$13,280,421
- Kevin Navin Sheth · Brigham And Women'S Hospital$10,362,027
- Dale Sandler · Social And Scientific Systems, Inc.$9,632,923
- Zhiyong Yang · Fzata, Inc.$7,816,062
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,152,405
- Phillip W Graham · Research Triangle Institute$7,075,871
Research focus
RecurrenceTumorResistanceSamplingGliomaExcisionMonitorLesionImageTumor TissuePre-Clinical ModelCohortExtracellularTranslational ProgressMetabolomicsMolecularCombined Modality TherapyMicrodialysisMetabolicClinical TrialsClinicGlioblastomaNeurosurgeryBurden Of Illness
Grant awards (10)
Glioma intelligence from behind enemy lines$525,455
R37 · FY2025 · CA · contact PI
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.$358,007
R33 · FY2025 · NS · contact PI
Assay Validation of Cell-free DNA Amplified DNA Junctions for High Grade Glioma Monitoring$266,736
UH2 · FY2025 · CA
Glioma intelligence from behind enemy lines$508,690
R37 · FY2024 · CA · contact PI
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.$385,574
R61 · FY2024 · NS · contact PI
Glioma intelligence from behind enemy lines$545,993
R37 · FY2023 · CA · contact PI
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.$397,500
R61 · FY2023 · NS · contact PI
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.$397,500
R61 · FY2022 · NS · contact PI
Impact of radiation-induced senescence on the glioblastoma microenvironment$199,512
R21 · FY2020 · NS · contact PI
Impact of radiation-induced senescence on the glioblastoma microenvironment$239,262
R21 · FY2019 · NS · contact PI